Cross‐protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity
Abstract:Mice previously infected with an aerosol of A/Rec 31 influenza virus were strongly protected against an aerosol challenge with A/Vic influenza as judged by lung virus titers recovered 2 days after the challenge infection. Such complete homotypic immunity was not achieved by priming with live Rec 31 virus injected i.v. or UV-inactivated Rec 31 virus administered s.c. together with Al(OH)3 and saponin. The reason for the superior protective effect of the natural infection was investigated. The protection induced… Show more
“…values for IgA in the BALF, further suggesting the importance of cross-reactive IgA for Het-I at the respiratory mucosa. In mice, cross-reactive IgA induced by natural infection was shown to be strongly correlated to protection from challenge with a heterologous homotypic virus [35]. Serum HI antibody titer and cross-reactive cytotoxic T-lymphocytes were not correlated with protection from infection, but instead were related to recovery [35].…”
Section: Discussionmentioning
confidence: 98%
“…Virus was not detected from any pigs in this group at any time point and macroscopic and microscopic lesions were both significantly reduced to minimal or undetectable levels. Live challenge and recovery or natural exposure to influenza virus has been well documented to have improved Het-I over inactivated vaccines [35][36][37][38]. To demonstrate the ability of the NS1 deletion mutant in inducing Het-I, vaccinated pigs were challenged with a heterologous H3N2 and a heterosubtypic rH1N1.…”
Section: Discussionmentioning
confidence: 99%
“…In mice, cross-reactive IgA induced by natural infection was shown to be strongly correlated to protection from challenge with a heterologous homotypic virus [35]. Serum HI antibody titer and cross-reactive cytotoxic T-lymphocytes were not correlated with protection from infection, but instead were related to recovery [35]. In addition, IgA was shown to be more cross-reactive than IgG against heterologous virus, and passive transfer of IgA to non-immune mice conferred protection [39], whereas mucosal administration of anti-IgA to immune mice blocked protection from re-infection with the same virus [40].…”
In the U.S., despite available swine influenza virus (SIV) vaccines, multiple influenza subtypes as well as antigenic and genetic variants within subtypes continue to circulate in the swine population. One of the challenges to control and eliminate SIV is that the currently used inactivated influenza virus vaccines do not provide adequate cross-protection against multiple antigenic variants of SIV in the field. We previously generated a recombinant H3N2 swine influenza virus (SIV) based on the influenza A/SW/TX/4199-2/98 virus (TX98) containing an NS1 gene expressing a truncated NS1 protein of 126 amino acids, TX98-NS1Δ126 virus. This recombinant strain was demonstrated to be highly attenuated in swine and showed potential for use as a modified live-virus vaccine (MLV) after intratracheal application in pigs. However, this route of inoculation is not practical for vaccination in the field. In the present study, we first compared intramuscular and intranasal routes of application of the MLV, and found that the intranasal route was superior in priming the local (mucosal) immune response. Pigs were then vaccinated via the intranasal route and challenged with wild type homologous TX98 H3N2 virus, with a genetic and antigenic variant H3N2 SIV (influenza A/SW/ CO/23619/99 virus, CO99) and a heterosubtypic H1N1 SIV (influenza A/SW/IA/00239/2004 virus, IA04). The intranasally vaccinated pigs were completely protected against homologous challenge. In addition, MLV vaccination provided nearly complete protection against the antigenic H3N2 variant CO99 virus. When challenged with the H1N1 IA04 virus, MLV vaccinated animals displayed reduced fever and virus titers despite minimal reduction in lung lesions. In vaccinated pigs, there was no serologic cross-reactivity by HI assays with the heterologous or heterosubtypic viruses. However, there appeared to be substantial cross-reactivity in antibodies at the mucosal level with the CO99 virus in MLV vaccinated pigs.
“…values for IgA in the BALF, further suggesting the importance of cross-reactive IgA for Het-I at the respiratory mucosa. In mice, cross-reactive IgA induced by natural infection was shown to be strongly correlated to protection from challenge with a heterologous homotypic virus [35]. Serum HI antibody titer and cross-reactive cytotoxic T-lymphocytes were not correlated with protection from infection, but instead were related to recovery [35].…”
Section: Discussionmentioning
confidence: 98%
“…Virus was not detected from any pigs in this group at any time point and macroscopic and microscopic lesions were both significantly reduced to minimal or undetectable levels. Live challenge and recovery or natural exposure to influenza virus has been well documented to have improved Het-I over inactivated vaccines [35][36][37][38]. To demonstrate the ability of the NS1 deletion mutant in inducing Het-I, vaccinated pigs were challenged with a heterologous H3N2 and a heterosubtypic rH1N1.…”
Section: Discussionmentioning
confidence: 99%
“…In mice, cross-reactive IgA induced by natural infection was shown to be strongly correlated to protection from challenge with a heterologous homotypic virus [35]. Serum HI antibody titer and cross-reactive cytotoxic T-lymphocytes were not correlated with protection from infection, but instead were related to recovery [35]. In addition, IgA was shown to be more cross-reactive than IgG against heterologous virus, and passive transfer of IgA to non-immune mice conferred protection [39], whereas mucosal administration of anti-IgA to immune mice blocked protection from re-infection with the same virus [40].…”
In the U.S., despite available swine influenza virus (SIV) vaccines, multiple influenza subtypes as well as antigenic and genetic variants within subtypes continue to circulate in the swine population. One of the challenges to control and eliminate SIV is that the currently used inactivated influenza virus vaccines do not provide adequate cross-protection against multiple antigenic variants of SIV in the field. We previously generated a recombinant H3N2 swine influenza virus (SIV) based on the influenza A/SW/TX/4199-2/98 virus (TX98) containing an NS1 gene expressing a truncated NS1 protein of 126 amino acids, TX98-NS1Δ126 virus. This recombinant strain was demonstrated to be highly attenuated in swine and showed potential for use as a modified live-virus vaccine (MLV) after intratracheal application in pigs. However, this route of inoculation is not practical for vaccination in the field. In the present study, we first compared intramuscular and intranasal routes of application of the MLV, and found that the intranasal route was superior in priming the local (mucosal) immune response. Pigs were then vaccinated via the intranasal route and challenged with wild type homologous TX98 H3N2 virus, with a genetic and antigenic variant H3N2 SIV (influenza A/SW/ CO/23619/99 virus, CO99) and a heterosubtypic H1N1 SIV (influenza A/SW/IA/00239/2004 virus, IA04). The intranasally vaccinated pigs were completely protected against homologous challenge. In addition, MLV vaccination provided nearly complete protection against the antigenic H3N2 variant CO99 virus. When challenged with the H1N1 IA04 virus, MLV vaccinated animals displayed reduced fever and virus titers despite minimal reduction in lung lesions. In vaccinated pigs, there was no serologic cross-reactivity by HI assays with the heterologous or heterosubtypic viruses. However, there appeared to be substantial cross-reactivity in antibodies at the mucosal level with the CO99 virus in MLV vaccinated pigs.
“…Indeed, it has been demonstrated in the mouse model that passive transfer of immunoglobulins protect against challenge with infectious influenza virus (Virelizier et al, 1976(Virelizier et al, , 1979. In addition the study of immunoglobulin isotypes stimulated by the inoculation of different virus preparations (Liew et al, 1984) has attempted to examine the antibody isotype involved in these protection mechanisms (Balkovic et al, 1987). With its widespread occurrence in the bloodstream, lymphatics and peripheral body fluids the antibody isotype IgG is likely to be the most important in neutralizing the virus (Possee et al, 1982).…”
SUMMARYThe IgG subclass responses to cold-adapted (ca) influenza A/Queensland/6/72 virus and purified haemagglutinin H3 was assessed in C57BL/6 and BALB/c mice. In BALB/c mice IgG2a was present as the major subclass in serum, lung and salivary secretions after two doses of ca virus. In contrast, the serum response in C57BL/6 mice was predominantly IgG1 after primary and secondary inoculations of ca virus. However, in lung and salivary secretions no specific subclass was dominant. When purified H3 was used as the inoculum, serum responses were dominated by IgGl in BALB/c mice after two inoculations whereas all four subclasses were present at equal levels in C57BL/6 mice. Overall the lung and salivary responses detected in C57BL/6 mice were lower than those observed in BALB/c mice with all four subclasses contributing equally to the response in BALB/c mice. The neutralizing and haemagglutination inhibition abilities of the four Protein A-Sepharose-purified IgG subclasses differed between the BALB/c, C57BL/6 and CBA/CaH mice strains. IgG1 and IgG2a were most effective in BALB/c mice and in C57BL/6 and CBA/CaH mice, IgG2a and IgG2b. These results are discussed in terms of the differing abilities of replicating and non-replicating virus to stimulate differential responses in mice and the TH1 and TH2 helper cell concept.
“…Foster nursing can confer homosubtypic protection, supporting a role for secretory IgA (14). Some reports have suggested that IgA in secretions may be more cross-reactive than IgG (15)(16)(17)(18)(19); such cross-reactivity may be a mechanism through which IgA could contribute to heterosubtypic immunity. Interference with viral replication or assembly during transcytosis (20,21), as suggested for rotavirus (22), is a potential mechanism that might be mediated by IgA Abs to conserved internal proteins.…”
The mechanisms of broad cross-protection to influenza viruses of different subtypes, termed heterosubtypic immunity, remain incompletely understood. We used knockout mouse strains to examine the potential for heterosubtypic immunity in mice lacking IgA, all Ig and B cells, NKT cells (CD1 knockout mice), or γδ T cells. Mice were immunized with live influenza A virus and compared with controls immunized with unrelated influenza B virus. IgA−/− mice survived full respiratory tract challenge with heterosubtypic virus that was lethal to controls. IgA−/− mice also cleared virus from the nasopharynx and lungs following heterosubtypic challenge limited to the upper respiratory tract, where IgA has been shown to play an important role. Ig−/− mice controlled the replication of heterosubtypic challenge virus in the lungs. Acute depletion of CD4+ or CD8+ T cell subsets abrogated this clearance of virus, thus indicating that both CD4+ and CD8+ T cells are required for protection in the absence of Ig. These results in Ig−/− mice indicate that CD4+ T cells can function by mechanisms other than providing help to B cells for the generation of Abs. Like wild-type mice, CD1−/− mice and γδ−/− mice survived lethal heterosubtypic challenge. Acute depletion of CD4+ and CD8+ cells abrogated heterosubtypic protection in γδ−/− mice, but not B6 controls, suggesting a contribution of γδ T cells. Our results demonstrate that the Ab and cellular subsets deficient in these knockout mice are not required for heterosubtypic protection, but each may play a role in a multifaceted response that as a whole is more effective than any of its parts.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.